Sonnet biotherapeutics appoints stephen mcandrew, ph.d. as chief business officer

Princeton, n.j., feb. 13, 2025 (globe newswire) -- sonnet biotherapeutics holdings, inc. (nasdaq:sonn) (the "company" or "sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of stephen j. mcandrew, ph.d., as chief business officer, effective february 17, 2025.
SONN Ratings Summary
SONN Quant Ranking